Vacinação no idoso
Palavras-chave:
Vacinação, imunização, idosoResumo
Este artigo de revisão tem por objetivo atualizar as recomendações de vacinação no idoso. O aumento da longevidade e a maior ocorrência e severidade de complicações associadas às doenças preveníveis pelas vacinas na população idosa tornam premente a necessidade de implementação de programas e políticas de saúde pública direcionadas para esta faixa etária.
Referências
Department of economic and social affairs world social report 2023: Leaving no one behind in an ageing world-United Nations.
World Health Organization (WHO). Immunization Agenda 2030: a global strategy to leave no one behind; 2022 [Acesso em: 2022 Nov 18].
Bloom D, Fan V, Sevilla J. The broad socioeconomic benefits of vaccination. Sci Transl Med. 2018;10 (441): eaaj234. DOI:10.1126/ scitranslmed.aaj2345.
Peck M, Gacic-Dobo M, Diallo M, Nedelec Y, Sodha S, Wallace A. Global routine vaccination coverage, 2018. MMWR Morb Mortal Wkly Rep. 2019; 68(42):937-42. DOI:10.15585/mmwr.mm6842a1.
Patel M, Dumolard L, Nedelec Y, Sodha S, Steulet C, Gacic-Dobo M, Kretsinger K, et al. Progress toward regional measles elimination — worldwide, 2000-2018. Morb Mortal Wkly Rep. 2019; 68(48):1105-11. DOI:10.15585/mmwr. mm6848a1.
Gavazzi G, Krause K. Ageing and infection. Lancet. 2002; 2:659-66. https://doi. org/10.1016/S1473-3099(02)00437-1).
A review of factors influencing vaccination policies and programs for older adults globally. Eiden AL, Barrattb J, Nyakua MK. Human Vaccines & Immunotherapeutics 2023; Vol. 19, NO. 1, 2157164 https://doi.org/10.1080/21645515.2022.2157164.
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018; 391(10127):1285-300.
Araújo R, Watanabe SF, Boiron L, Pereira ACPR, Asano E. Economic impact of influenza infection in Brazil: analysis from the health systems and society perspective in 2019. J Bras Econ Saúde 2021; 13(3):300-9. DOI: 10.21115/JBES.v13.n3.p300-9.
Webster RG, Bean WJ, Jr. Genetics of influenza virus. Annu Rev Genet. 1978; 12:415-31.
Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, et al. Triple reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med. 2009; 360(25):2616-25.
Silva PCR. Tese de Doutorado Biologia Celular e Molecular: Dinâmica Molecular dos vírus Influenza A (H1N1) Pandêmico em cinco anos de circulação no Brasil.
Christman MC, Kedwaii A, Xu J, Donis RO, Lu G. Pandemic (H1N1) 2009 virus revisited: An evolutionary retrospective. Infect Genet Evol. 2011; 11(5):803-11.
Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol. 2011; 9(8):590-603.
Ministério da Saúde. Informe Técnico Operacional. Vacinação contra a Influenza; Brasília 2023.
Barros et al. Patterns of influenza B circulation in Brazil and its relevance to seasonal vaccine composition. Braz J Infect Dis 20 (1); 2016. doi.org/10.1016/j.bjid.2015.09.009
Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Rajaram S, Boikos C, Gelone DK, and Gandhi A. Ther Adv Vaccines Immunother. 2020; 8: 2515135520908121. Published online 2020 Feb 22. DOI: 10.1177/2515135520908121.
Lee JKH, Lam GKL, Shin T, et al. Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta- analysis. Vaccine 2021; 39 Suppl 1:A24. Supported by Sanofi Pasteur.
https://www.cdc.gov/flu/prevent/qa_fluzone.htm
https://www.uptodate.com/contents/seasonal-influenza-vaccination-in-adults?source= mostViewed_widget
Perdrizet J, et al. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil Infants. Human Vaccines & Immunotherapeutics. 2020; 17(4): 1162-1172.
Simell B, et al. Pneumococcal Carriage Group. The fundamental link between pneumococcal carriage and disease. Expert Review of Vaccines 2012; 11: 841-855.
Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 16(6):335-367, 2018.
Almeida S, et al. Low prevalence of Pneumococcal carriage and high serotype and genotype diversity among adults over 60 years of age living in Portugal. PLOS ONE. 9(3): e90974, 2014.
Arguedas A, et al. Upper Respiratory Tract Colonization with Streptococcus pneumoniae in adults. Expert Review of Vaccines. 19(4):353-366, 2020.
Centers for Disease Control and Prevention (CDC). 2020. National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. Pneumococcal Disease. Disponível em: https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html. Acesso em: 01 Jun 2021.
Krone CL, et al. Immunosenescence and pneumococcal disease: an imbalance in host pathogen inteactions. Lancet Respir Med 2014; 2:141-153.
Austrian R & Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann. Intern. Med. 1964; 60:759-76.
Centers for Disease Control and Prevention (CDC). 2005. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Motal Wkly Rep. 54: 893 – 897, 2005.
Centers for Disease Control and Prevention (CDC). 2020. Biggest Threats and Data CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report). DOI: https://www.cdc.gov/drugresistance/biggest-threats.html Acesso em: 23.07.2021.
Paton JC, Trappetti C. Streptococcus pneumoniae capsular polysaccharide. Microbiol Spectrum 2018; 7(2): GPP3 - 0019.
Brueggemann AB, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. v. 3, n. 11, p. 11- 168. Nov. 2007
https://sbim.org.br/calendarios-de-vacinacao
https://www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html
https://www.cdc.gov/mmwr/volumes/72/rr/rr7203a1.htm#T2_down
Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341.
Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1.
United States Centers for Disease Control and Prevention. Shingles Surveillance. DOI: http://www.cdc.gov/shingles/surveillance.html (Acesso em: 01 Jul 2016).
Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32:1481.
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology 2008; 115:S3.
Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217.
Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341.
UpToDate: herpes zoster Mary A Albrecht, MD; Myron J Levin, MD. This topic last updated: Feb 24, 2022.
Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087.
Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375:1019.
Boutry C, Hastie A, Diez-Domingo J, et al. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clin Infect Dis 2022; 74:1459.
Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018; 14:1370.
Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin. Infect. Dis. 2021; 73, 949-956.
Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Clin. Infect. Dis. 2021; 73, 941-948.
Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80.
https://www.uptodate.com/contents/vaccination-for-the-prevention-of-shingles-herpes-zoster.
Colindres R, Wascotte V, Brecx A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 2020; 16:2628.
Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep 2019; 68:91.
Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103.
https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html
https://sbim.org.br/images/calendarios/calend-sbim-idoso.pdf
COVID-19 Cumulative Infection Collaborators Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis. Lancet. 2022;399(10344):2351. Epub 2022 Apr 8.
https://www.cdc.gov/vaccines/vpd/rsv/public/older-adults.html
Papi A, Ison MG, Langley JM, et al.; AReSVi-006 Study Group. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med 2023; 388:595-608. DOI: https://www.nejm.org/doi/10.1056/NEJMoa2209604. PMID:36791160.
Walsh EE, Pérez Marc G, Zareba AM, et al.; RENOIR Clinical Trial Group. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med 2023; 388:1465–77. DOI: https://www.nejm.org/doi/10.1056/NEJMoa2213836. PMID:37018468.
Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72:793–801. DOI: http://dx.doi.org/10.15585/mmwr.mm7229a4.
